- New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
- Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)
- FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
- Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
- New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
- Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types
- Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging
- Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy
- Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
- Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash
More ▼
Key statistics
On Tuesday, Roche Holding AG (RHHVF:QXI) closed at 338.72, 9.77% above its 52-week low of 308.57, set on Mar 31, 2021.
52-week range
Markit short selling activity
Open | 336.41 |
---|---|
High | 339.00 |
Low | 334.50 |
Bid | -- |
Offer | -- |
Previous close | 335.50 |
Average volume | 3.71k |
---|---|
Shares outstanding | 862.56m |
Free float | 721.95m |
P/E (TTM) | 18.78 |
Market cap | 270.23bn CHF |
EPS (TTM) | 16.52 CHF |
Annual div (ADY) | 9.82 USD |
---|---|
Annual div yield (ADY) | 2.93% |
Div ex-date | Mar 18 2021 |
Div pay-date | Mar 22 2021 |
Data delayed at least 15 minutes, as of Apr 20 2021 20:50 BST.
More ▼